PFIZER2019-10-012019-12-31in-bse-fin:OneOperatingExpenses01Member PFIZER2019-10-012019-12-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares PFIZER 2019-04-01 2020-03-31 2020-02-03 INR Crores Third quarter Single segment Pharmaceuticals 2019-10-01 2019-12-31 Unaudited Standalone 5381800000.00 582200000.00 5964000000.00 1048400000.00 1039300000.00 -79700000.00 899800000.00 24600000.00 247000000.00 1139600000.00 4319000000.00 1645000000.00 0.00 1645000000.00 415500000.00 -161100000.00 254400000.00 0.00 1390600000.00 0.00 0.00 0.00 0.00 1390600000.00 -12400000.00 1378200000.00 0.00 0.00 457500000.00 10 30.40 30.40 0.00 0.00 30.40 30.40 NOTES: n n1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on February 14, 2020 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date. n n2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards (‘Ind AS”) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016. n n3. The financial results for quarter and nine months ended December 31, 2019 have been subjected to limited review by the statutory auditors of the Company. The limited review report does not contain any modifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company’s website - www.pfizerindia.com n n4. Effective April 01, 2019 the Company adopted Ind AS 116 “Leases” using the modified retrospective method. Accordingly, comparatives for the period / quarter have not been retrospectively adjusted. n n5. The Company elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognized Provision for Income Tax for the nine months ended December 31, 2019 and remeasured its deferred tax assets and deferred tax liabilities basis the rate prescribed in the said section. The full impact of this change has been recognized in the Statement of Profit and Loss. n n6. During the quarter, the Company divested rights and interests in two brands for a consideration of Rs 37 crore (December 31, 2018: Rs 30 crore). The income, net of related expenses and deferment of revenue as per Ind AS 115 on account of supply arrangement, is included in ‘Other Income’ amounting to Rs 25 crore (December 31, 2018: Rs 29 crore) for the quarter ended 31 December 2019. n n7. The Company has only one segment which is ‘Pharmaceuticals’. Therefore disclosure relating to segments is not applicable and accordingly not made. Single segment 2019-04-01 2019-12-31 Unaudited Standalone 16496400000.00 1388000000.00 17884400000.00 2549900000.00 2855300000.00 607300000.00 2638600000.00 72300000.00 748300000.00 3206800000.00 12678500000.00 5205900000.00 0.00 5205900000.00 1452700000.00 -308000000.00 1144700000.00 0.00 4061200000.00 0.00 0.00 0.00 0.00 4061200000.00 -37400000.00 4023800000.00 0.00 0.00 457500000.00 10 88.77 88.77 0.00 0.00 88.77 88.77 Other Expenses 1139600000.00 Other Expenses 3206800000.00